Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-602-6 | CAS number: 123-11-5
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well documented study report which meets basic scientific principles
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Standardised test to assess the acute toxicity of the test substance after i.p. application in mice (BASF-Test).
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Anisaldehyde
- EC Number:
- 204-602-6
- EC Name:
- Anisaldehyde
- Cas Number:
- 123-11-5
- Molecular formula:
- C8 H8 O2
- IUPAC Name:
- 4-methoxybenzaldehyde
- Details on test material:
- - Name of test material (as cited in study report): Anisaldehyd
- Physical state: liquid
- Analytical purity: > 99 % (data from order sheet)
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: WIGA
- Mean weight per test group at study initiation: 22-28 g (males); 22-24 g (females)
- Fasting period before study: 15-20 h
- Diet: Herilan MRH-Haltung, H. Eggersmann KG ad libitum
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- aqueous 0.5% CMC solution
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 2% - 20%
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg - Doses:
- 200, 700, 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Weighing was performed at the beginning of the study and on days 3-4, 7 and 13. Observation of clinical signs was several times on the day of administration and once daily afterwards with the exception of weekends and on holidays
- Necropsy of survivors performed: yes
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 700 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 2000 mg/kg bw: 10/10
700 mg/kg bw: 0/10
200 mg/kg bw: 0/10 - Clinical signs:
- 2000 mg/kg: dyspnoea, apathy, abnormal position, staggering, atonia, loss of cornea reflex, twitching, narcotic like state, poor general condition
700 mg/kg: dyspnoea, apathy, abnormal position, staggering, twitching, tremor, poor general condition
200 mg/kg: no adverse effects - Body weight:
- The body weight gain was within the normal range.
- Gross pathology:
- Animals that died or were sacrificed after post observation period: no intra-abdominal substance precipitations or adhesions.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
